Number of Intermediate- and High-Risk Factors Significantly Predicts Biochemical Survival and Prostate Cancer-Specific Survival After Low-Dose-Rate Brachytherapy

被引：0
|
作者：
Shasha, D. [1 ]
Salant, R. [1 ]
Sivathayalan, A. [2 ]
Farrell, P. J. [2 ]
Mourad, W. F. [1 ]
Harrison, L. B. [1 ]
机构：
[1] Mt Sinai Beth Israel Med Ctr, New York, NY USA
[2] Carleton Univ, Ottawa, ON K1S 5B6, Canada
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2015年 / 93卷 / 03期
关键词：
D O I：
10.1016/j.ijrobp.2015.07.1172
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2617
引用
收藏
页码：E248 / E249
页数：2
相关论文
共 50 条
  • [1] Interstitial low dose rate brachytherapy for prostate cancer - A focus on intermediate- and high-risk disease
    Khaksar, S. J.
    Langley, S. E. M.
    Lovell, D.
    Laing, R. W.
    CLINICAL ONCOLOGY, 2006, 18 (07) : 513 - 518
  • [2] RADIATION DOSE PREDICTS FOR BIOCHEMICAL CONTROL IN INTERMEDIATE-RISK PROSTATE CANCER PATIENTS TREATED WITH LOW-DOSE-RATE BRACHYTHERAPY
    Ho, Alice Y.
    Burri, Ryan J.
    Cesaretti, Jamie A.
    Stone, Nelson N.
    Stock, Richard G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (01): : 16 - 22
  • [3] Dose escalation with HDR brachytherapy for intermediate- and high-risk prostate cancer
    Chicas-Sett, R.
    Celada, F.
    Burgos, J.
    Farga, D.
    Perez-Calatayud, M.
    Roldan, S.
    Collado, E.
    Ibanez, B.
    Perez-Calatayud, J.
    Tormo, A.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S380 - S381
  • [4] Long-Term Efficacy and Toxicity of Low-Dose-Rate 125I Prostate Brachytherapy as Monotherapy in Low-, Intermediate-, and High-Risk Prostate Cancer
    Kittel, Jeffrey A.
    Reddy, Chandana A.
    Smith, Kristin L.
    Stephans, Kevin L.
    Tendulkar, Rahul D.
    Ulchaker, James
    Angermeier, Kenneth
    Campbell, Steven
    Stephenson, Andrew
    Klein, Eric A.
    Wilkinson, D. Allan
    Ciezki, Jay P.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (04): : 884 - 893
  • [5] Outcomes of High-Dose Rate Brachytherapy for Intermediate- to High-Risk Prostate Cancer at One Institution
    Lin, E. Y.
    Lee, A.
    Demanes, J.
    Kamrava, M.
    Venkat, P. S.
    Hagio, M. A.
    Zaide, L. B.
    Park, S. J.
    Zarate, C.
    Chang, A. J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : E927 - E927
  • [6] Biochemical control in intermediate- and high-risk prostate cancer after EBRT with and without brachytherapy boost
    Moll, Matthias
    Magrowski, Lukasz
    Mittlboeck, Martina
    Heinzl, Harald
    Kirisits, Christian
    Ciepal, Jakub
    Masri, Oliwia
    Heilemann, Gerd
    Stando, Rafal
    Krzysztofiak, Tomasz
    Depowska, Gabriela
    d'Amico, Andrea
    Techmanski, Tomasz
    Kozub, Anna
    Majewski, Wojciech
    Suwinski, Rafal
    Wojcieszek, Piotr
    Sadowski, Jacek
    Widder, Joachim
    Goldner, Gregor
    Miszczyk, Marcin
    STRAHLENTHERAPIE UND ONKOLOGIE, 2025, 201 (01) : 11 - 19
  • [7] Prostate-specific antigen nadir after high-dose-rate brachytherapy predicts long-term survival outcomes in high-risk prostate cancer
    Tsumura, Hideyasu
    Satoh, Takefumi
    Ishiyama, Hiromichi
    Tabata, Ken-ichi
    Komori, Shouko
    Sekiguchi, Akane
    Ikeda, Masaomi
    Kurosaka, Shinji
    Fujita, Tetsuo
    Kitano, Masashi
    Hayakawa, Kazushige
    Iwamuro, Masatsugu
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2016, 8 (02) : 95 - 103
  • [8] Focal low-dose-rate prostate brachytherapy for low- and intermediate-risk prostate cancer
    Kunogi, Hiroaki
    Wakumoto, Yoshiaki
    Kawamoto, Terufumi
    Oshima, Masaki
    Horie, Shigeo
    Sasai, Keisuke
    JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2020, 12 (06) : 554 - 561
  • [9] Low toxicity of focal low-dose-rate (LDR) brachytherapy for intermediate risk prostate cancer
    Harkin, Timothy
    Smyth, Lloyd
    Anderson, Elliot
    O'Sullivan, Richard
    Ryan, Andrew
    Lawrentschuk, Nathan
    Katz, Darren
    Grummet, Jeremy
    See, Andrew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 76 - 76
  • [10] Intermediate-Risk Prostate Cancer Treated With Definitive Low-dose-rate Brachytherapy
    Ester, E. C.
    Wang, X.
    Vernon, M. R.
    Olson, N. J.
    Shanley, R. M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2012, 84 (03): : S405 - S405
12345